Diekstra, Meta H M <br/><br/>
CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma.  [electronic resource] 

 -  European urology  Oct 2015 
 - 621-9 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1873-7560 
<br/><br/><label>Standard No.: </label>10.1016/j.eururo.2015.04.018  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>ATP Binding Cassette Transporter, Subfamily B--genetics<br/>Aged<br/>Antineoplastic Agents--adverse effects<br/>Carcinoma, Renal Cell--drug therapy<br/>Cytochrome P-450 CYP3A--genetics<br/>Disease Progression<br/>Disease-Free Survival<br/>Female<br/>Haplotypes<br/>Humans<br/>Indoles--adverse effects<br/>Kaplan-Meier Estimate<br/>Kidney Neoplasms--drug therapy<br/>Male<br/>Middle Aged<br/>Netherlands<br/>Ohio<br/>Pharmacogenetics<br/>Polymorphism, Single Nucleotide<br/>Proportional Hazards Models<br/>Protein Kinase Inhibitors--adverse effects<br/>Pyrroles--adverse effects<br/>Risk Factors<br/>Spain<br/>Sunitinib<br/>Time Factors<br/>Treatment Outcome